Physician profile
Thomas C Key
NPI 1205862158
$641.84
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.40 · 2020: $129 · 2021: $361 · 2022: $57.69 · 2024: $48.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $148.16 | 2019-2022 | |
| Exeltis, USA INC. | $94.24 | 2020-2021 | |
| Aspira Women'S Health INC | $88.82 | 2021-2022 | |
| Hologic Sales and Service, LLC | $46.36 | 2020-2024 | Thinprep 2000 Processor, Aptima |
| Daiichi Sankyo INC. | $38.24 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $34.32 | 2019-2021 | |
| Evofem Biosciences, INC. | $31.39 | 2021 | |
| Agile Therapeutics, INC. | $30.51 | 2021 | |
| Merck Sharp & Dohme LLC | $30.47 | 2020-2021 | |
| Astellas Pharma US INC | $26.68 | 2024 | Veozah |
| Therapeuticsmd, INC. | $12.97 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.81 | 2020 | |
| Shield Therapeutics INC | $12.40 | 2022 | |
| Convatec INC. | $11.87 | 2021 | |
| Mylan Pharmaceuticals INC. | $11.78 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $10.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Key listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.